Sökning: onr:"swepub:oai:lup.lub.lu.se:db4cb1a0-ead8-4b6d-b738-f5799f601b37" > The path to a bette...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08817naa a2201225 4500 | |
001 | oai:lup.lub.lu.se:db4cb1a0-ead8-4b6d-b738-f5799f601b37 | |
003 | SwePub | |
008 | 200305s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/db4cb1a0-ead8-4b6d-b738-f5799f601b372 URI |
024 | 7 | a https://doi.org/10.1002/path.54062 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a for2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Gonzalez-Ericsson, Paulau Vanderbilt University Medical Center4 aut |
245 | 1 0 | a The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice |
264 | c 2020-04-09 | |
264 | 1 | b Wiley,c 2020 |
300 | a 18 s. | |
520 | a Immune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD‐L1 expression on immune cells occupying ≥1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab‐paclitaxel. However, concerns regarding variability between immunohistochemical PD‐L1 assay performance and inter‐reader reproducibility have been raised. High tumor‐infiltrating lymphocytes (TILs) have also been associated with response to PD‐1/PD‐L1 inhibitors in patients with breast cancer (BC). TILs can be easily assessed on hematoxylin and eosin–stained slides and have shown reliable inter‐reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Because TILs and PD‐L1 are parts of an immunological spectrum in BC, we propose the systematic implementation of combined PD‐L1 and TIL analyses as a more comprehensive immuno‐oncological biomarker for patient selection for PD‐1/PD‐L1 inhibition‐based therapy in patients with BC. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk‐management framework that may help mitigate the risks of suboptimal patient selection for immuno‐therapeutic approaches in clinical trials and daily practice based on combined TILs/PD‐L1 assessment in BC. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a PD-L1 | |
653 | a Breast cancer | |
700 | 1 | a Stovgaard, Elisabeth Su Gentofte Hospital,Herlev Hospital,University of Copenhagen4 aut |
700 | 1 | a Sua, Luz Fu ICESI University4 aut |
700 | 1 | a Reisenbichler, Emilyu Yale University4 aut |
700 | 1 | a Kos, Zuzanau British Columbia Cancer Agency4 aut |
700 | 1 | a Carter, Jodi Mu Mayo Clinic Minnesota4 aut |
700 | 1 | a Michiels, Stefanu University of Paris-Saclay4 aut |
700 | 1 | a Le Quesne, Johnu University of Cambridge,University of Leicester4 aut |
700 | 1 | a Nielsen, Torsten Ou University of British Columbia4 aut |
700 | 1 | a Laenkholm, Anne Vibekeu Zealand University Hospital4 aut |
700 | 1 | a Fox, Stephen Bu University of Melbourne4 aut |
700 | 1 | a Adam, Julienu Institut Gustave Roussy4 aut |
700 | 1 | a Bartlett, John M Su Ontario Institute for Cancer Research,University of Edinburgh4 aut |
700 | 1 | a Rimm, David Lu Yale University4 aut |
700 | 1 | a Quinn, Cecilyu University College Dublin4 aut |
700 | 1 | a Peeters, Dieteru HistoGeneX NV4 aut |
700 | 1 | a Dieci, Maria Vu University of Padova4 aut |
700 | 1 | a Vincent-Salomon, Anneu Curie Institute, Paris4 aut |
700 | 1 | a Cree, Ianu International Agency for Research on Cancer, World Health Organization4 aut |
700 | 1 | a Hida, Akira Iu Matsuyama Shimin Hospital4 aut |
700 | 1 | a Balko, Justin Mu Vanderbilt University Medical Center4 aut |
700 | 1 | a Haynes, Harry Ru University of Bristol4 aut |
700 | 1 | a Frahm, Isabelu Sanatorio Mater Dei4 aut |
700 | 1 | a Acosta-Haab, Gabrielau Hospital Maria Curie4 aut |
700 | 1 | a Balancin, Marcelou University of São Paulo4 aut |
700 | 1 | a Bellolio, Enriqueu University of La Frontera4 aut |
700 | 1 | a Yang, Wentaou Fudan University Shanghai Cancer Center (FUSCC)4 aut |
700 | 1 | a Kirtani, Pawanu Manipal Hospitals Dwarka4 aut |
700 | 1 | a Sugie, Tomoharuu Kansai Medical University4 aut |
700 | 1 | a Ehinger, Annau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital4 aut0 (Swepub:lu)pat-amm |
700 | 1 | a Castaneda, Carlos Au Instituto Nacional de Enfermedades Neoplasicas4 aut |
700 | 1 | a Kok, Marleenu Netherlands Cancer Institute4 aut |
700 | 1 | a McArthur, Heatheru Cedars-Sinai Medical Center4 aut |
700 | 1 | a Siziopikou, Kalliopiu Northwestern University4 aut |
700 | 1 | a Badve, Sunilu Indiana University4 aut |
700 | 1 | a Fineberg, Susanu Montefiore Medical Center4 aut |
700 | 1 | a Gown, Allen Mu PhenoPath Laboratories4 aut |
700 | 1 | a Viale, Giuseppeu University of Milan,European Institute of Oncology4 aut |
700 | 1 | a Schnitt, Stuart Ju Dana-Farber Cancer Institute,Brigham and Women's Hospital / Harvard Medical School4 aut |
700 | 1 | a Pruneri, Giancarlou University of Milan,Istituto Nazionale dei Tumori4 aut |
700 | 1 | a Penault-Llorca, Frédérique Mu University of Auvergne4 aut |
700 | 1 | a Hewitt, Stephenu National Cancer Institute, NCI4 aut |
700 | 1 | a Thompson, Aubreyu Mayo Clinic Florida4 aut |
700 | 1 | a Allison, Kimberly Hu Stanford University4 aut |
700 | 1 | a Symmans, William Fu University of Texas4 aut |
700 | 1 | a Bellizzi, Andrew Mu University of Iowa Hospitals4 aut |
700 | 1 | a Brogi, Ediu Memorial Sloan-Kettering Cancer Center4 aut |
700 | 1 | a Moore, David A.u UCL Cancer Institute4 aut |
700 | 1 | a Larsimont, Denisu Institut Jules Bordet4 aut |
700 | 1 | a Dillon, Deborah Au Dana-Farber Cancer Institute4 aut |
700 | 1 | a Lazar, Alexanderu University of Texas4 aut |
700 | 1 | a Lien, Huangchunu National Taiwan University Hospital4 aut |
700 | 1 | a Goetz, Matthew Pu Mayo Clinic Minnesota4 aut |
700 | 1 | a Broeckx, Glennu Antwerp University Hospital4 aut |
700 | 1 | a El Bairi, Khalidu Mohamed Premier University4 aut |
700 | 1 | a Harbeckj, Nadiau University Hospital Munich4 aut |
700 | 1 | a Cimino-Mathews, Ashleyu Johns Hopkins Hospital4 aut |
700 | 1 | a Sotiriou, Christosu Institut Jules Bordet,Université Libre de Bruxelles (ULB)4 aut |
700 | 1 | a Adams, Sylviau New York University4 aut |
700 | 1 | a Liu, Shi-weiu Sichuan Cancer Hospital and Institute4 aut |
700 | 1 | a Loibl, Sibylleu German Breast Group4 aut |
700 | 1 | a Chen, I-Chunu National Taiwan University Hospital4 aut |
700 | 1 | a Lakhani, Sunil Ru Royal Brisbane and Women's Hospital,University of Queensland4 aut |
700 | 1 | a Juco, Jonathan Wu Merck Sharp And Dohme Corp., US4 aut |
700 | 1 | a Denkert, Carstenu University Hospital Giessen and Marburg4 aut |
700 | 1 | a Blackley, Elisabeth Fu Peter MacCallum Cancer Centre4 aut |
700 | 1 | a Demaria, Sandrau Weill Cornell Medicine4 aut |
700 | 1 | a Leon-Ferre, Robertou Mayo Clinic Minnesota4 aut |
700 | 1 | a Gluz, Olegu Johanniter Krankenhaus4 aut |
700 | 1 | a Zardavas, Dimitriosu Bristol-Myers Squibb4 aut |
700 | 1 | a Emancipator, Kennethu Merck Sharp And Dohme Corp., US4 aut |
700 | 1 | a Ely, Scottu Bristol-Myers Squibb4 aut |
700 | 1 | a Loi, Shereneu Peter MacCallum Cancer Centre4 aut |
700 | 1 | a Salgado, Robertou Institut Jules Bordet,University of Antwerp4 aut |
700 | 1 | a Sanders, Melindau Vanderbilt University Medical Center4 aut |
710 | 2 | a Vanderbilt University Medical Centerb Gentofte Hospital4 org |
773 | 0 | t Journal of Pathologyd : Wileyg 250:5, s. 667-684q 250:5<667-684x 1096-9896x 0022-3417 |
856 | 4 | u http://dx.doi.org/10.1002/path.5406y FULLTEXT |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/path.5406 |
856 | 4 8 | u https://lup.lub.lu.se/record/db4cb1a0-ead8-4b6d-b738-f5799f601b37 |
856 | 4 8 | u https://doi.org/10.1002/path.5406 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy